Expert Rev Anti Infect Ther. 2013;11(12):1333-1353. Considering currently available data on the PK of polymyxins, it can be concluded that there are some PK advantages of polymyxin B over CMS ...

We developed a PD model for the vehicle control group and PK/PD models for the treated groups. First, the tumor natural growth model was established, and the parameters of the control group are ...

I gave the course by Zoom in September to 70 scientists at the FDA. We consider ourselves evangelists for PK/PD. Every May, we offer the same three-day course in Niagara Falls for pharmaceutical ...

Methods: Clinical data from 36 subjects (doses from 4-300 mg QD) from the phase I study JNJ-26854165-CAN-1001 were used for PK and PKPD modeling. Plasma concentrations were used as input for the ...

Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of initiation of the planned RLYB116 confirmatory clinical PK/PD study, the ...

Results: MLN8237 was absorbed rapidly (median T max, 2h).PK was variable. Steady-state exposures were achieved by 7D and were dose-proportional over 5-200mg/day. The recommended phase II dose × 7D ...

Expert Rev Anti Infect Ther. 2013;11(12):1333-1353. The PK/PD index associated with microbiological activity of fosfomycin is still not elucidated and both concentration- and time-dependent ...